Characteristics of patients with sorafenib-treated advanced hepatocellular carcinoma eligible for second-line treatment
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Characteristics of patients with sorafenib-treated advanced hepatocellular carcinoma eligible for second-line treatment
Authors
Keywords
Hepatocellular carcinoma, Sorafenib, Second-line, Regorafenib, Resorce
Journal
INVESTIGATIONAL NEW DRUGS
Volume 36, Issue 2, Pages 332-339
Publisher
Springer Nature
Online
2017-09-12
DOI
10.1007/s10637-017-0507-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update
- (2017) Masao Omata et al. Hepatology International
- Albumin-Bilirubin grade predicts prognosis of HCC patients with sorafenib use
- (2017) Yuan-Hung Kuo et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Jordi Bruix et al. LANCET
- Post-progression survival in patients with advanced hepatocellular carcinoma resistant to sorafenib
- (2016) Sadahisa Ogasawara et al. INVESTIGATIONAL NEW DRUGS
- Regional differences in sorafenib-treated patients with hepatocellular carcinoma: GIDEON observational study
- (2016) Masatoshi Kudo et al. LIVER INTERNATIONAL
- Analysis of Sorafenib Outcome: Focusing on the Clinical Course in Patients with Hepatocellular Carcinoma
- (2016) Sadahisa Ogasawara et al. PLoS One
- Sorafenib treatment in Child–Pugh A and B patients with advanced hepatocellular carcinoma: safety, efficacy and prognostic factors
- (2015) Sadahisa Ogasawara et al. INVESTIGATIONAL NEW DRUGS
- Randomized Controlled Trial of the Prophylactic Effect of Urea-Based Cream on Sorafenib-Associated Hand-Foot Skin Reactions in Patients With Advanced Hepatocellular Carcinoma
- (2015) ZhengGang Ren et al. JOURNAL OF CLINICAL ONCOLOGY
- Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial
- (2015) Andrew X Zhu et al. LANCET ONCOLOGY
- Determinants of Survival After Sorafenib Failure in Patients With BCLC-C Hepatocellular Carcinoma in Real-World Practice
- (2015) I-Cheng Lee et al. MEDICINE
- Advances in targeted therapies for hepatocellular carcinoma in the genomic era
- (2015) Josep M. Llovet et al. Nature Reviews Clinical Oncology
- Effectiveness of Sorafenib in Patients with Transcatheter Arterial Chemoembolization (TACE) Refractory and Intermediate-Stage Hepatocellular Carcinoma
- (2015) Tadaaki Arizumi et al. Liver Cancer
- EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
- (2015) et al. JOURNAL OF HEPATOLOGY
- The preclinical development of regorafenib for the treatment of colorectal cancer
- (2014) Koh Miura et al. Expert Opinion on Drug Discovery
- Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib
- (2014) Andrew X. Zhu et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib
- (2014) Maria Reig et al. JOURNAL OF HEPATOLOGY
- Efficacy of Sorafenib in Intermediate-Stage Hepatocellular Carcinoma Patients Refractory to Transarterial Chemoembolization
- (2014) Sadahisa Ogasawara et al. ONCOLOGY
- JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan
- (2014) Masatoshi Kudo et al. Liver Cancer
- Postprogression survival of patients with advanced hepatocellular carcinoma: Rationale for second-line trial design
- (2013) Maria Reig et al. HEPATOLOGY
- Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study
- (2013) Josep M. Llovet et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognosis of patients with advanced hepatocellular carcinoma who failed first-line systemic therapy
- (2013) Yu-Yun Shao et al. JOURNAL OF HEPATOLOGY
- Prospective Study of Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: An Asian Cooperative Study between Japan and Korea
- (2013) Masafumi Ikeda et al. JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY
- Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
- (2012) George D Demetri et al. LANCET
- Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
- (2012) Axel Grothey et al. LANCET
- Management of hepatocellular carcinoma: An update
- (2011) Jordi Bruix et al. HEPATOLOGY
- Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity
- (2010) Scott M. Wilhelm et al. INTERNATIONAL JOURNAL OF CANCER
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search